Atty Docket: ONYX1027-DIV1 Serial No. 09/687,230

## In the Claims

Claims 1 – 7 (Canceled)

Claim 8 (currently amended): An isolated phosphatidylinositol-3' kinase associated protein comprising the polypeptide of SEQ ID No. 2 wherein the C-terminal amino acids of said phosphatidylinositol-3' kinase associated protein bind and that binds to the intermediate src homology 2 (SH2) domain on the regulatory subunit of phosphatidylinositol-3' kinase by the associated protein(s) C terminal amino acids.

Claim 9 (currently amended): An isolated phosphatidylinositol-3' kinase

associated protein of claim 8 wherein a bromodomain comprises amino acids

151 313 of SEQ ID No. 2 amino acids 151-313 of SEQ ID No. 2 encode a bromodomain.

Claim 10 (cancelled)

Claim 11 (previously amended): A chimeric protein comprising said

phosphatidylinositol-3' kinase associated protein(s) of claim 10 fused to a

heterologous polypeptide.

Claims 12 – 22 (canceled)

Claim 23 (currently amended): An isolated phosphatidylinositol-3' kinase

associated protein comprising an amino acid sequence, said amino acid sequence

comprising the C-terminal amino acids of SEQ. ID No. 2 that bind to the

intermediate src homology 2 (SH2) domain on the regulatory subunit of

Sent By: Onyx Pharmaceuticals;

Atty Docket; ONYX1027-DIV1 Serial No. 09/687,230

phosphatidylinositol-3' kinase, which amino acid sequence is encoded by a polynucleotide nucleotide sequence-which hybridizes under stringent conditions to the polynucleotide nucleotide sequence set forth in SEQ ID No. 1, wherein said stringent conditions comprise hybridization to filter-bound polynucleotide in 0.5M NaHPO4, 7% sodium dodecyl sulfate, 1mM EDTA at 65 degrees centigrade, and washing in 0.1X SSC/0.1%SDS at 68 degrees centigrade.